Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab in Children With Resistant Nephrotic Syndrome
NCT02394106Phase 2Terminated
- Sponsor
- Istituto Giannina Gaslini
- Start
- Jul 2015
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in nephrotic syndrome comparing Ofatumumab with Placebo (2 arms). Primary endpoint: Complete or partial disease remission at 6 months. Started Jul 2015; status: terminated.
02
Drugs
ofatumumab
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT02394106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02394106.